Biotech Values

[DewDiligence]

NVS launches Zarxio (Neupogen FoB) at ~15% price discount:

http://www.wsj.com/articles/novartis-to-begin-selling-copy-of-amgens-neupogen-in-u-s-1441263475

A Novartis spokesman said the company would sell Zarxio at a 15% discount to Neupogen, based on list prices. For example, a 300-microgram syringe of Zarxio would list for $275.77, compared with $324.30 for an equivalent dose of Neupogen.

Zarxio is the first drug approved under the FDA’s 351(k) pathway for FoBs. Although approved by the FDA in Mar 2015, Zarxio couldn’t be launched until now because the US Appellate Court ruled that a 6-month delay was the penalty for NVS’ refusal to participate in the 351(k) “patent dance” process specified in the 351(k) statute (#msg-115571193, #msg-115579876).